

*Short Report*

**More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis**

Andrew Blauvelt • Kilian Eyerich • Alan D. Irvine • Marjolein de Bruin-Weller • Shawn G. Kwatra • Melinda Gooderham • Brian Kim • Brian M. Calimlim • Wan-Ju Lee • Eliza M. Raymundo • Yingyi Liu • Sarah Ofori • Andrew M. Platt • Jonathan I. Silverberg

**Author Affiliations:**

A. Blauvelt

Blauvelt Consulting LLC, Lake Oswego, OR, USA

K. Eyerich

Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany

A. D. Irvine

Clinical Medicine, Trinity College Dublin and Wellcome-HRB Clinical Research Facility, St James's Hospital, Dublin, Ireland

M. de Bruin-Weller

National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, Netherlands

S. G. Kwatra

Johns Hopkins University School of Medicine, Department of Dermatology, Baltimore, MD, USA

M. Gooderham

SKiN Centre for Dermatology, Peterborough, Ontario, Canada

M. Gooderham

Probit Medical Research, Peterborough, Ontario, Canada

M. Gooderham

Department of Medicine, Queen's University, Kingston, Ontario, Canada

B. Kim

Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

B. Kim

Mark Lebwohl Center for Neuroinflammation and Sensation, Icahn School of Medicine at Mount Sinai, New York, NY, USA

B. Kim

Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

B. Kim

Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

B. M. Calimlim • W-J. Lee • E. M. Raymundo • Y. Liu • S. Ofori • A. M. Platt

AbbVie Inc., North Chicago, IL, USA

J. I. Silverberg

Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

### **Correspondence**

A. Blauvelt


Blauvelt Consulting LLC





Lake Oswego, OR, USA

e-mail: [blauveltconsults@gmail.com](mailto:blauveltconsults@gmail.com)


Phone: +1 503.245.1525

**Fig. S1** Time spent in skin clearance and itch response states through 16 weeks of treatment with upadacitinib (Measure Up 1 and Measure Up 2 studies). **a** Mean proportion of days spent with an EASI response state. **b** Mean proportion of days spent with an EASI 90 response. **c** Median number of days spent with an EASI 90 response. **d** Mean proportion of days spent with no/minimal itch for patients with WP-NRS > 1 at baseline, defined as a WP-NRS 0/1 response. **e** Median number of days spent with no/minimal itch for patients with WP-NRS > 1 at baseline, defined as a WP-NRS 0/1 response. **f** Mean proportion of days spent in an itch-improved state for patients with WP-NRS  $\geq 4$  at baseline, defined as WP-NRS improvement  $\geq 4$  from baseline. **g** Median number of days spent in an itch-improved state for patients with WP-NRS  $\geq 4$  at baseline, defined as WP-NRS improvement  $\geq 4$  from baseline. *EASI* Eczema Area and Severity Index, *EASI 100/90/75/50* improvements from baseline in EASI of 100%/ $\geq 90\%$ / $\geq 75\%$ / $\geq 50\%$ , *UPA* upadacitinib, *WP-NRS* Worst Pruritus Numerical Rating Scale







**Fig. S2** Time spent in itch response states through 4 weeks of treatment with upadacitinib (Measure Up 1 and Measure Up 2 studies). **a** Mean proportion of days spent with no/minimal itch for patients with WP-NRS > 1 at baseline, defined as a WP-NRS 0/1 response. **b** Median number of days spent with no/minimal itch for patients with WP-NRS > 1 at baseline, defined as a WP-NRS 0/1 response. **c** Mean proportion of days spent in an itch-improved state for patients with WP-NRS  $\geq 4$  at baseline, defined as WP-NRS improvement  $\geq 4$  from baseline. **d** Median number of days spent in an itch-improved state for patients with WP-NRS  $\geq 4$  at baseline, defined as WP-NRS improvement  $\geq 4$  from baseline. UPA upadacitinib, WP-NRS Worst Pruritus Numerical Rating Scale




**Fig. S3** Time spent in skin clearance and itch response states through 16 weeks of treatment with upadacitinib versus dupilumab (Heads Up study). **a** Mean proportion of days spent with an EASI response state. **b** Mean proportion of days spent with an EASI 90 response. **c** Median number of days spent with an EASI 90 response. **d** Mean proportion of days spent with no/minimal itch for patients with WP-NRS > 1 at baseline, defined as a WP-NRS 0/1 response. **e** Median number of days spent with no/minimal itch for patients with WP-NRS > 1 at baseline, defined as a WP-NRS 0/1 response. **f** Mean proportion of days spent in an itch-improved state for patients with WP-NRS  $\geq 4$  at baseline, defined as WP-NRS improvement  $\geq 4$  from baseline. **g** Median number of days spent in an itch-improved state for patients with WP-NRS  $\geq 4$  at baseline, defined as WP-NRS improvement  $\geq 4$  from baseline. *DUPI* dupilumab, *EASI* Eczema Area and Severity Index, *EASI 100/90/75/50* improvements from baseline in EASI of 100%/ $\geq 90\%$ / $\geq 75\%$ / $\geq 50\%$ , *UPA* upadacitinib, *WP-NRS* Worst Pruritus Numerical Rating Scale




**d**




**e**




**f**



**g**




**Fig. S4** Time spent in skin clearance and itch response states through 24 weeks of treatment with upadacitinib versus dupilumab (Heads Up study). **a** Mean proportion of days spent with an EASI response state. **b** Mean proportion of days spent with an EASI 90 response. **c** Median number of days spent with an EASI 90 response. **d** Mean proportion of days spent with no/minimal itch for patients with WP-NRS > 1 at baseline, defined as a WP-NRS 0/1 response. **e** Median number of days spent with no/minimal itch for patients with WP-NRS > 1 at baseline, defined as a WP-NRS 0/1 response. **f** Mean proportion of days spent in an itch-improved state for patients with WP-NRS  $\geq 4$  at baseline, defined as WP-NRS improvement  $\geq 4$  from baseline. **g** Median number of days spent in an itch-improved state for patients with WP-NRS  $\geq 4$  at baseline, defined as WP-NRS improvement  $\geq 4$  from baseline. *DUPI* dupilumab, *EASI* Eczema Area and Severity Index, *EASI 100/90/75/50* improvements from baseline in EASI of 100%/ $\geq 90\%$ / $\geq 75\%$ / $\geq 50\%$ , *UPA* upadacitinib, *WP-NRS* Worst Pruritus Numerical Rating Scale







**d**




**e**



**f**



**g**



**Fig S5** Time spent in itch response states through 4 weeks of treatment with upadacitinib versus dupilumab (Heads Up study). **a** Mean proportion of days spent with no/minimal itch for patients with WP-NRS > 1 at baseline, defined as a WP-NRS 0/1 response. **b** Median number of days spent with no/minimal itch for patients with WP-NRS > 1 at baseline, defined as a WP-NRS 0/1 response. **c** Mean proportion of days spent in an itch-improved state for patients with WP-NRS  $\geq 4$  at baseline, defined as WP-NRS improvement  $\geq 4$  from baseline. **d** Median number of days spent in an itch-improved state for patients with WP-NRS  $\geq 4$  at baseline, defined as WP-NRS improvement  $\geq 4$  from baseline. *DUPI* dupilumab, *UPA* upadacitinib, *WP-NRS* Worst Pruritus Numerical Rating Scale

